Efficacy and Safety of Glutamine-supplemented Parenteral Nutrition in Surgical ICU Patients: An American Multicenter Randomized Controlled Trial

Study answer

What this study found

Glutamine-supplemented PN was safe but did not improve clinical outcomes versus standard PN. Six-month mortality was 31.4% with GLN-PN and 29.7% with STD-PN (hazard ratio 1.05, 95% CI 0.58-1.88; P = 0.88), and 28-day mortality was 14.7% versus 16.0%. Hospital-acquired infections were also similar, with any infection in 52 GLN-PN events versus 39 STD-PN events and rates of 28 versus 25 per 1000 hospital days (P = 0.70). No serious adverse event was related to the study PN.

Study & population

This was a 1:1 randomized controlled trial at 5 US centers in 150 adult surgical ICU patients requiring parenteral nutrition after cardiac, vascular, or intestinal surgery.

Intervention

The active regimen was intravenous parenteral nutrition supplemented with alanyl-glutamine dipeptide at 0.5 g/kg/day, delivered as a 20% alanyl-glutamine dipeptide solution admixed into PN and continued for up to 28 days after enrollment.

Key limitation

The trial enrolled only 150 postoperative SICU patients, limiting power to detect modest benefits or harms.

View full study detailsView sourceOpen PDF

Original abstract